Telogen Effluvium. Telogen effluvium
Conditions
Interventions
Intervention 1: Intervention group number 1: This group will take 3 Gernahair Premium capsules orally for 6 months. This supplement contains 90 mg thiamine, 180 mg calcium pantothenate, 300 mg medicin
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with a history of hair loss who had clinical findings of female pattern hair loss (FPHL) Ludwig type II or I and parietal center telogen hair rate of more than 20%, as determined by TrichoScan Patients with diffuse hair loss without any evidence of underlying disease in medical history Patients with acquired or age-related damage to the hair structure, including thinning, brittle, or split end hair Patients with nail growth disorders such as soft or brittle nails with no evidence of underlying disease in the medical history
Exclusion criteria
Exclusion criteria: Symptomatic diffuse alopecia (eg, due to iron deficiency or thyroid disorder) FPHL Ludwig type III Androgenic alopecia with or without virile symptoms as a result of polycystic ovaries, late-onset adrenogenital syndrome and ovarian, adrenal, or pituitary tumors Systemic autoimmune diseases Debilitating diseases (eg, AIDS or malignancy) Alopecia Areata Inflammatory ulcer or other ulcerative alopecia Other inflammatory conditions affecting the scalp (such as seborrheic dermatitis, psoriasis, or contact dermatitis) Receiving any treatment for hair loss or participating in another clinical trial for 3 months before entering the study Receiving medications that may cause hair loss (such as anticoagulants, lipid-lowering drugs, retinoids, antiepileptic drugs, antithyroid drugs, androgens, progesterones with androgenic or relative toxic effects, Angiotensin Converting Enzyme inhibitors(ACE) ) within 3 months before entering the study. Receiving drugs containing sulfonamides (interference with PABA) Initiation or termination of hormone replacement therapy or hormonal contraception within 6 months before entering the study Any type of hormone replacement therapy or oral contraceptive containing progesterone with an androgenic effect (such as Norethisterone, Norgestrel, levonorgestrel, Linsternol or Tibolone) Pregnancy or breastfeeding Known sensitivity to any of components
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anagen hair rate. Timepoint: Before treatment, after 3 and 6 months of treatment. Method of measurement: Measuring the anagen hair rate in an area equal to 1.8 square centimeters in the center of the parietal of the scalp, while imaging the specific area and using the Trichoscan software.;Hair count. Timepoint: Before treatment, after 3 and 6 months of treatment. Method of measurement: Measuring the hair count in an area equal to 1.8 square centimeters in the center of the parietal of the scalp, while imaging the specific area and using the Trichoscan software.;Hair density. Timepoint: Before treatment, after 3 and 6 months of treatment. Method of measurement: Measuring the hair density in an area equal to 1.8 square centimeters in the center of the parietal of the scalp, while imaging the specific area and using the Trichoscan software.;Cumulative hair shaft diameter. Timepoint: Before treatment, after 3 and 6 months of treatment. Method of measurement: Measuring the cumulative hair shaft diameter in an area equal to 1.8 square centimeters in the center of the parietal of the scalp, while imaging the specific area and using the Trichoscan software. | — |
Secondary
| Measure | Time frame |
|---|---|
| Participant's satisfaction with treatment. Timepoint: Before treatment, after 3 and 6 months of treatment. Method of measurement: The patient's overall satisfaction with the treatment will be evaluated from 0 to 100 so that 0 is a sign of absolute dissatisfaction and 100 is a sign of maximum consumer satisfaction. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Nasimi
Tehran University of Medical Sciences
Outcome results
None listed